SeaStar Medical Holding Statistics
Total Valuation
ICU has a market cap or net worth of $11.98 million. The enterprise value is $1.96 million.
| Market Cap | 11.98M |
| Enterprise Value | 1.96M |
Important Dates
The last earnings date was Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ICU has 4.02 million shares outstanding. The number of shares has increased by 442.80% in one year.
| Current Share Class | 4.02M |
| Shares Outstanding | 4.02M |
| Shares Change (YoY) | +442.80% |
| Shares Change (QoQ) | +8.19% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 3.28% |
| Float | 3.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.64 |
| Forward PS | 7.54 |
| PB Ratio | 1.49 |
| P/TBV Ratio | 1.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.73 |
| Quick Ratio | 2.41 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -459.85 |
Financial Efficiency
Return on equity (ROE) is -302.01% and return on invested capital (ROIC) is -174.31%.
| Return on Equity (ROE) | -302.01% |
| Return on Assets (ROA) | -79.24% |
| Return on Invested Capital (ROIC) | -174.31% |
| Return on Capital Employed (ROCE) | -163.44% |
| Weighted Average Cost of Capital (WACC) | -1.19% |
| Revenue Per Employee | $84,471 |
| Profits Per Employee | -$699,941 |
| Employee Count | 17 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 1.96 |
Taxes
In the past 12 months, ICU has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.24% in the last 52 weeks. The beta is -1.03, so ICU's price volatility has been lower than the market average.
| Beta (5Y) | -1.03 |
| 52-Week Price Change | -75.24% |
| 50-Day Moving Average | 3.94 |
| 200-Day Moving Average | 4.21 |
| Relative Strength Index (RSI) | 40.21 |
| Average Volume (20 Days) | 84,505 |
Short Selling Information
The latest short interest is 141,315, so 3.51% of the outstanding shares have been sold short.
| Short Interest | 141,315 |
| Short Previous Month | 154,907 |
| Short % of Shares Out | 3.51% |
| Short % of Float | 3.55% |
| Short Ratio (days to cover) | 1.82 |
Income Statement
In the last 12 months, ICU had revenue of $1.44 million and -$11.90 million in losses. Loss per share was -$4.19.
| Revenue | 1.44M |
| Gross Profit | 1.34M |
| Operating Income | -11.96M |
| Pretax Income | -11.90M |
| Net Income | -11.90M |
| EBITDA | n/a |
| EBIT | -11.96M |
| Loss Per Share | -$4.19 |
Balance Sheet
The company has $9.35 million in cash and $331,000 in debt, with a net cash position of $9.02 million or $2.24 per share.
| Cash & Cash Equivalents | 9.35M |
| Total Debt | 331,000 |
| Net Cash | 9.02M |
| Net Cash Per Share | $2.24 |
| Equity (Book Value) | 7.32M |
| Book Value Per Share | 1.83 |
| Working Capital | 6.82M |
Cash Flow
| Operating Cash Flow | -13.71M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | -45,000 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 93.11% |
| Operating Margin | -832.59% |
| Pretax Margin | -828.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ICU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -442.80% |
| Shareholder Yield | -442.80% |
| Earnings Yield | -108.41% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ICU is $10.00, which is 235.57% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.00 |
| Price Target Difference | 235.57% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | 134.93% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 5, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 5, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |